U24AI183840

Pathogen Data Network - Summary

The Pathogen Data Network (PDN) will nucleate global networks around the mobilization of diverse biodata types, including host and pathogen genomics, transcriptomics, proteins, pathways and networks, imaging and cohorts.

The integration and linkage of these data for the purposes of research and public health response will be made possible through the development of a technical framework including specifications, standards, interfaces and reference software implementations.

All the publicly available data to be integrated with further datasets and tools from a range of pathogen-related data resources will be made accessible and re-usable under the Pathogens Portal (PP), hosted at EMBL-EBI, and within distributed local pathogen portals (LPP), hosted globally and enabling additional functionalities to be customized for the specific local context.

To foster data mobilization, PDN will establish a network of FAIR local data hubs (LDH) based on reference software implementations to be deployed on locally controlled cloud infrastructure, ideally in countries having signed the Nagoya Protocol.

To achieve trustworthy and equitable sharing of the mobilized data to international repositories, legally compliant with local regulations as well as aligned to international policy, we will also address in-depth issues of trust and ownership and work to provide data-sharing policy options for international and national organizations, ensuring alignment of the PDN project with international policy and its wide adoption by end users.

This will include LDH focusing on low and middle income countries.

In parallel, we will establish a LDH managers' community of practice to exchange knowledge and expertise, with a focus on capacity building, harmonization and preparedness.

Data hubs (DH) hosted centrally will continue existing in parallel, supporting those who lack capacity, resource or expertise to deploy and maintain a LDH.

LDH would be able to host personal sensitive data that may not be openly shared but can be made discoverable and accessible for research and public health under proper legal and ethical frameworks.

The Pathogen Analysis System (PAS) will be extended with additional workflows from selected use cases spanning global sewage data, foodborne viruses and linked clinical-epidemiological data.

PDN will enable its users to run analyses centrally for DH, and locally or remotely for LDHs.

An extensive and global support, outreach and training program will fuel the adoption of the network concept, the connection of infrastructure to its interfaces, and the use of open pathogen data by the global scientific community - both for research and for decision-making.

In summary, PDN will develop the networks and all the underpinning components at the technical-, analytical-, trust-, policy-, training- and outreach-levels to truly enable data mobilization and sharing, and the subsequent data integration and linking into a global knowledgebase network serving research needs thanks to open access to data, and public health needs, including preparedness and response, thanks to timely access to controlled-access data and a dedicated surveillance and outbreak dashboard.

SIB Institut Suisse De Bioinformatique

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Switzerland

Foreign

Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed) (RFA-AI-23-032)

Amendment Since initial award the total obligations have increased 100% from $2,767,750 to $5,535,500.